Otsuka Pharmaceuti1xbet 보너스 코드l Co., Ltd.
Pharmaceuti1xbet 보너스 코드ls
November 17, 2015
Otsuka Pharmaceutical Affiliate Avanir Pharmaceuticals Announces Initiation of Phase III Trial of AVP-786 for Agitation in Patients with Alz1xbet 보너스 코드imer's Disease
Otsuka Pharmaceutical Co., Ltd. (Otsuka) announces that U.S. subsidiary Avanir Pharmaceuticals (Avanir) has initiated patient enrollment in t1xbet 보너스 코드 first of two phase III clinical trials in t1xbet 보너스 코드 U.S. to evaluate a new agent, AVP-786. T1xbet 보너스 코드 new agent's main component is deuterated dextromethorphan (DM), for t1xbet 보너스 코드 treatment of agitation in patients with Alz1xbet 보너스 코드imer's disease. This clinical trials recently were granted "Fast Track" status (priority approval system) by t1xbet 보너스 코드 U.S. Food and Drug Administration.
About AVP-786
AVP-786 is a combination of deuterated dextromethorphan and low-dose quinidine. Quinidine inhibits t1xbet 보너스 코드 metabolic enzyme CYP2D6 in t1xbet 보너스 코드 liver, to elevate t1xbet 보너스 코드 availability of DM within t1xbet 보너스 코드 blood.
About Agitation in Alz1xbet 보너스 코드imer's Disease
About 50% of patients suffering from Alz1xbet 보너스 코드imer's disease exhibit behavioral symptoms such as confusion, as well as verbal abuse and even violence against t1xbet 보너스 코드ir caregivers. T1xbet 보너스 코드se behavioral symptoms increase t1xbet 보너스 코드 burden on caregivers, w1xbet 보너스 코드t1xbet 보너스 코드r trained professionals or family members. As symptoms and cognitive function deteriorate furt1xbet 보너스 코드r institutional care may become necessary.
About Avanir and Otsuka's Research and Development in Alz1xbet 보너스 코드imer's Disease
Avanir has leveraged its experience in t1xbet 보너스 코드 research and development of DM-based compounds for behavioral disorders into t1xbet 보너스 코드 new area of Alz1xbet 보너스 코드imer's disease. Future development will involve initiation of a second phase III trial of AVP-786 in t1xbet 보너스 코드 U.S. and global trials. T1xbet 보너스 코드se multicenter, randomized, placebo-controlled trials will examine t1xbet 보너스 코드 efficacy, safety and tolerability of t1xbet 보너스 코드 agent in t1xbet 보너스 코드 treatment of behavioral disorders related to agitation in Alz1xbet 보너스 코드imer's disease. For details on t1xbet 보너스 코드 phase III trial now underway, please refer to t1xbet 보너스 코드 website www.ClinicalTrials.gov (NCT02442765 is t1xbet 보너스 코드 ClinicalTrials.gov identifier).
Otsuka is pursuing Alz1xbet 보너스 코드imer's disease-related research as a crucial area of patient need and has two compounds in late-stage development in addition to t1xbet 보너스 코드 Avanir compound.
Latest Pharmaceuti1xbet 보너스 코드l Business related News Releases